Alpha Pro Tech Ltd. - Q2 2003 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2003. Alpha Pro Tech, Ltd. manufactures and distributes disposable protective apparel, infection control products (masks and shields), extended care products, and consumer goods (pet beds). The company operates primarily in the United States, serving medical, dental, industrial safety, and clean room markets.
Key Financial Metrics
| Metric | Q2 2003 (3 Months) | Q2 2002 (3 Months) | YTD 2003 (6 Months) | YTD 2002 (6 Months) |
|---|---|---|---|---|
| Sales | $8,707,000 | $5,805,000 | $13,951,000 | $11,008,000 |
| Gross Margin | 54.9% | 52.9% | 53.8% | 49.9% |
| Net Income | $1,364,000 | $668,000 | $1,829,000 | $1,089,000 |
| Diluted EPS | $0.06 | $0.03 | $0.08 | $0.05 |
| Cash Balance | $2,216,000 | $1,236,000 | $2,216,000 | $1,236,000 |
| Working Capital | $8,492,000 | $7,050,000 | $8,492,000 | $7,050,000 |
| Debt | $0 | $415,000 | $0 | $415,000 |
Note: Debt figures reflect the balance at period end. The company paid off all notes payable during Q2 2003.
Material Changes vs. Prior Period
- Revenue Surge: Sales increased 50.0% in Q2 2003 compared to Q2 2002. This was driven primarily by a ~$3 million increase in N-95 mask and eye shield sales due to the SARS outbreak, which accounted for approximately one-third of the quarter's revenue.
- Profitability: Net income more than doubled (104.2% increase) to $1.364 million. Gross margins improved due to a higher mix of high-margin mask sales and increased manufacturing in China.
- Segment Performance:
- Mask & Shield: Sales jumped 254.1% to $4.462 million.
- Apparel: Sales declined 6.2% to $3.920 million due to weakness in the semiconductor clean room market, partially offset by growth in the pharmaceutical sector.
- Extended Care: Sales decreased 11.0% to $325,000.
- Balance Sheet: The company eliminated all debt ($370,000 in equipment loans) during the quarter. Accounts receivable increased significantly ($2.53 million) due to the surge in sales volume.
Outlook, Risks, and Management Commentary
- SARS Impact: Management anticipates approximately $1.0 million in SARS-related revenue for Q3 2003. However, they note that sales in China have decreased significantly since June 30, and $0.9 million in orders have been put on hold or cancelled. The company has doubled N-95 production capacity to handle potential future outbreaks.
- Market Conditions: The semiconductor clean room market remains weak, with no recovery expected until 2004. Conversely, sales to the pharmaceutical and dental markets are improving.
- Liquidity: The company is debt-free with $2.216 million in cash and a $3.5 million credit facility (with $3.187 million available). Management believes current resources are sufficient for working capital and planned capital expenditures.
- Capital Allocation: The company repurchased 290,000 shares for $274,000 in Q1 2003. No shares were repurchased in Q2 2003. A new $500,000 buyback authorization was approved in March 2003.
- Risks: Results are sensitive to foreign currency exchange rates (manufacturing in Mexico and China) and the volatility of demand related to health crises like SARS.
Investor Verification Checklist
- SARS Revenue Sustainability: Verify the extent of cancelled orders ($0.9 million) and the actual realization of the projected $1.0 million Q3 SARS revenue.
- Semiconductor Market Exposure: Assess the long-term impact of the weak semiconductor clean room market on the Apparel segment, which management expects to remain depressed until 2004.
- Working Capital Efficiency: Monitor the high increase in accounts receivable ($2.53 million) relative to cash flow from operations ($115,000) to ensure collection rates remain healthy.
- Debt-Free Status: Confirm the company maintains its debt-free status and does not need to draw on its credit facility to fund operations or inventory buildup.